Attached files
file | filename |
---|---|
EX-5.1 - OPINION - AzurRx BioPharma, Inc. | ex5-1.htm |
EX-1.1 - UNDERWRITING AGREEMENT - AzurRx BioPharma, Inc. | ex1-1.htm |
S-1/A - AMENDMENT NO. 6 TO FORM S-1 - AzurRx BioPharma, Inc. | azurrxs1a-am6_sep2016.htm |
Exhibit
23.1
CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent
to the use in the Prospectus constituting part of the Registration
Statement on the Amendment No. 6 to Form S-1 (No. 333-212511) of
our report dated June 15, 2016, related to the financial statements
of Protea Europe SAS (“Predecessor”) for the period
January 1, 2014 through May 31, 2014; and our report dated June 15,
2016, related to the consolidated financial statements of AzurRx
BioPharma, Inc. as of December 31, 2015 and 2014 and for the year
ended December 31, 2015 and the period January 30, 2014 (date of
inception) through December 31, 2014 which appear in such
Prospectus. The report for AzurRx BioPharma, Inc. includes an
explanatory paragraph about the existence of substantial doubt
concerning its ability to continue as a going concern. We also
consent to the reference to our Firm under the caption
“Experts” in such Prospectus.
/s/ WeiserMazars
LLP
New York, New
York
October 4,
2016